Mylan Agrees to $465 Million EpiPen Settlement With U.S.
- Shares gain late Friday after drugmaker announces agreement
- Company also gets inquiry from SEC asking about Medicaid
Mylan NV's EpiPen allergy shots sit on display for a photograph in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
Mylan NV will pay the U.S. government $465 million in a swift settlement over how the drugmaker charged Medicaid for its allergy shot EpiPen.
The settlement will resolve part of the controversy over Mylan’s price increases on EpiPen, which enraged patients, prompted probes from Congress and cut a quarter of the value of Mylan’s stock since August. The shares gained in late trading Friday, rising 11 percent to $39.72.